TMC Looks To Add cSSSI Drug, Antibiotic Capabilities With Targanta Offer
Proposed merger would see The Medicines Company take over development of oritavancin, stalled at FDA due to “complete response” letter.
Proposed merger would see The Medicines Company take over development of oritavancin, stalled at FDA due to “complete response” letter.